@article{99182309fd0c450bbbade32ea45f6ec7,
title = "Comment on “PGA×BSA composite versus PASI: Comparison across disease severities and as therapeutic response measure for Cal/BD foam in plaque psoriasis”",
author = "Mark Lebwohl",
note = "Funding Information: Disclosure: Dr Mark Lebwohl is an employee of Mount Sinai and receives research funds from AbbVie, Amgen, Arcutis, Boehringer Ingelheim, Dermavant Sciences, Eli Lilly, Incyte, Janssen Research and Development, LLC, LEO Pharma, Ortho Dermatologics, Pfizer, SciDerm, and UCB, Inc and is a consultant for Aditum Bio, Allergan, Almirall, Arcutis, Inc, Avotres Therapeutics, BirchBioMed Inc, BMD Skincare, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, Dermavant Sciences, Evelo, Facilitate International Dermatologic Education, Foundation for Research and Education in Dermatology, Inozyme Pharma, LEO Pharma, Meiji Seika Pharma, Menlo Therapeutics Inc, Mitsubishi, NeuroDerm, Pfizer, Promius/Dr. Reddy's Laboratories, Serono, Theravance, and Verrica.",
year = "2020",
month = oct,
doi = "10.1016/j.jaad.2020.04.125",
language = "English",
volume = "83",
pages = "e289--e290",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "4",
}